Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Multinational, Randomised, Double-blind, Parallel- Group, 24-week Placebo-controlled Study With 28-week Extension to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO)

NCT04612725 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04612725
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04612725 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Multinational, Randomised, Double-blind, Parallel- Group, 24-week Placebo-controlled Study With 28-week Extension to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO)
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Terminated
Start date
October 27, 2020
Completion date
March 28, 2023
Enrollment
159 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

chronic spontaneous urticaria